Publications by authors named "A S Kubasch"
Article Synopsis
- Lenalidomide (LEN) can help 60-70% of patients with del(5q) myelodysplastic neoplasm achieve independence from red blood cell transfusions (RBC-TI), but there's a concern about its toxicity and cost.
- The HARMONY Alliance study followed 118 low-intermediate risk MDS patients who discontinued LEN, finding that 50 lost RBC-TI after a median of 49 months.
- Factors like having a low transfusion burden before treatment, completing at least 12 LEN cycles, being younger, and having higher hemoglobin levels at withdrawal were linked to longer RBC-TI duration after discontinuing LEN.
Article Synopsis
- Advancements in understanding myelodysplastic neoplasms (MDS) have revealed important cellular and molecular factors that influence disease progression, highlighting the significance of immune dysregulation in the bone marrow during MDS evolution.
- Despite these advancements, immunotherapy for MDS has lagged due to a lack of effective immune classifications for patient stratification and no widely accepted immune panels for clinical use.
- To address these challenges, the i4MDS consortium proposes standardized immune monitoring approaches, including flow cytometry panels and cytokine assays, aiming to improve patient stratification and develop predictive markers for treatment response in MDS.
Article Synopsis
- Researchers investigated markers that might predict how well patients with relapsed/refractory multiple myeloma respond to CAR T cell therapy, which currently lack clarity.* -
- They found that nonresponders had an immunosuppressive microenvironment with high levels of certain immune cells that hinder CD8 T cell and natural killer cell activity.* -
- The study also revealed that CAR T cells from nonresponders displayed exhausted characteristics, suggesting potential targets like PD1 to enhance therapy effectiveness.*
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells.
View Article and Find Full Text PDF